微针和5-fluorouracil用于治疗稳定性 Vitiligo 在迄今未研究的高患病率人群中

相关实验视频

Updated: May 10, 2026

09:38

Direct Reprogramming of Mouse Fibroblasts into Melanocytes

Published on: August 27, 2021

2.0K

B Abhirami¹, Prabhat Kumar¹, Dharmendra K Mishra¹

¹From the Department of Dermatology, Venereology, Leprosy - Mahatma Gandhi Memorial Medical College and Hospital, Jamshedpur and Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.

Indian journal of dermatology

|December 9, 2024

概括

使用5-甲微针有效治疗稳定的白风斑,在91%的患者中实现显著的再发色. 这种组合疗法为高发病率地区的白风管理提供了有前途的选择.

科学领域:

皮肤病学皮肤病学
皮肤外科手术皮肤外科手术
化品皮肤学化品皮肤学

背景情况:

Vitiligo 影响全球人口的 0.25%,在某些地区的流行率更高,如印度的 Jharkhand (> 1%).
这种情况显著影响自尊,人际关系和心理健康,往往导致抑郁症.
已确立的医学治疗方法存在,但像使用5-甲进行微针等程序的有效性需要在不同人群中进一步验证.

研究的目的:

为了评估结合微针和局部5%的5-甲在稳定白风斑块的再颜色化中的有效性.
评估高发病率人群的治疗结果,在此之前还没有研究过这种特定干预措施.

主要方法:

一项干预性研究涉及30名年龄在10-50岁的患有稳定的白风的患者.
治疗包括微针,然后是局部5%的5-甲,每15天服用一次,两年内进行12次访问 (2019年9月至2021年9月).
用分级尺度 (优秀,非常好,好,差) 评估重颜色,并使用Chi-square测试或两个比例之间的标准差异误差分析数据.

主要成果:

尽管有COVID-19的干扰,但77%的计划样本 (23名患者) 完成了研究.
显著多数患者取得了积极的结果,91%的患者表现出良好的或很好的再颜色化 (21/23患者),56% (13/23) 获得了良好的或非常好的结果.
在8次访问 (4个月) 中,复原颜色的平均值为54%,并且在各种患者人口统计和白风特征中一致. 常见的副作用包括可控疼痛和短暂的多色素.

结论:

微针与5%的5-甲相结合,在治疗稳定的白风方面表现出显著的疗效,有91%的患者实现了良好的或优秀的再颜色化.
不论年龄,性别,病变部位,大小,稳定性或家族病史,在不同患者亚组中都观察到治疗的有效性.
这项研究提供了强有力的证据,支持使用微针和5-甲作为治疗白风的可行治疗选择,特别是在高患病率的人群中.

关键词:

5 - - 甲是一种甲.微针制造的微针制造一个稳定的白风.

相关概念视频

02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...